2-[18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans.

Alane S. Kimes, Andrew Horti, Edythe D. London, Svetlana I. Chefer, Carlo Contoreggi, Monique Ernst, Phyllis Friello, Andrei O. Koren, Varughese Kurian, John A. Matochik, Olga Pavlova, D. Bruce Vaupel, Alexey G. Mukhin

Research output: Contribution to journalArticle

Abstract

Noninvasive imaging of nicotinic acetylcholine receptors (nAChRs) in the human brain in vivo is critical for elucidating the role of these receptors in normal brain function and in the pathogenesis of brain disorders. Here we report the first in vivo visualization of human brain areas containing nAChRs by using PET and 2-[18F]fluoro-3-(2(S)azetidinylmethoxy)pyridine (2-[18F]FA). We acquired scans from six healthy non-smoking volunteers after i.v. bolus administration of 2-[18F]FA (1.6 MBq/kg or 0.043 +/- 0.002 mCi/kg). This dose was sufficient for visualizing nAChRs in the thalamus up to 5 h after injection. There were no adverse effects associated with administration of no-carrier-added 2-[18F]FA (1.3-10 pmol/kg). Consistent with the distribution of nAChRs in human brain, accumulated radioactivity was greatest in thalamus, intermediate in the midbrain, pons, cerebellum, and cortex; and least in white matter. As approximately 90% of the injected radioactivity was eliminated via the urine (biological half-life ca. 4 h), the urinary bladder wall received the highest radiation dose. The estimate of radiation dose equivalent to the urinary bladder wall (ca. 180 +/- 30 mSv/MBq or 0.7 rem/mCi with a 2.4 h void interval) suggests that multiple studies could be performed in a single subject. The results predict that quantitative PET imaging of nAChRs in human brain with 2-[18F]FA is feasible.

Original languageEnglish (US)
Pages (from-to)1331-1333
Number of pages3
JournalFASEB Journal
Volume17
Issue number10
StatePublished - 2003
Externally publishedYes

Fingerprint

Nicotinic Receptors
Neuroimaging
Brain
Imaging techniques
Thalamus
Radioactivity
Urinary Bladder
Dosimetry
Radiation
Pons
Brain Diseases
Mesencephalon
Cerebellum
Half-Life
Volunteers
2-fluoro-3-(2(S)-azetidinylmethoxy)pyridine
2-fluoro-3-(2-azetidinylmethoxy)pyridine
Urine
Visualization
Injections

Cite this

Kimes, A. S., Horti, A., London, E. D., Chefer, S. I., Contoreggi, C., Ernst, M., ... Mukhin, A. G. (2003). 2-[18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB Journal, 17(10), 1331-1333.

2-[18F]F-A-85380 : PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. / Kimes, Alane S.; Horti, Andrew; London, Edythe D.; Chefer, Svetlana I.; Contoreggi, Carlo; Ernst, Monique; Friello, Phyllis; Koren, Andrei O.; Kurian, Varughese; Matochik, John A.; Pavlova, Olga; Vaupel, D. Bruce; Mukhin, Alexey G.

In: FASEB Journal, Vol. 17, No. 10, 2003, p. 1331-1333.

Research output: Contribution to journalArticle

Kimes, AS, Horti, A, London, ED, Chefer, SI, Contoreggi, C, Ernst, M, Friello, P, Koren, AO, Kurian, V, Matochik, JA, Pavlova, O, Vaupel, DB & Mukhin, AG 2003, '2-[18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans.', FASEB Journal, vol. 17, no. 10, pp. 1331-1333.
Kimes, Alane S. ; Horti, Andrew ; London, Edythe D. ; Chefer, Svetlana I. ; Contoreggi, Carlo ; Ernst, Monique ; Friello, Phyllis ; Koren, Andrei O. ; Kurian, Varughese ; Matochik, John A. ; Pavlova, Olga ; Vaupel, D. Bruce ; Mukhin, Alexey G. / 2-[18F]F-A-85380 : PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. In: FASEB Journal. 2003 ; Vol. 17, No. 10. pp. 1331-1333.
@article{efbf7588d9b341cc9c3cb4a84252b75d,
title = "2-[18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans.",
abstract = "Noninvasive imaging of nicotinic acetylcholine receptors (nAChRs) in the human brain in vivo is critical for elucidating the role of these receptors in normal brain function and in the pathogenesis of brain disorders. Here we report the first in vivo visualization of human brain areas containing nAChRs by using PET and 2-[18F]fluoro-3-(2(S)azetidinylmethoxy)pyridine (2-[18F]FA). We acquired scans from six healthy non-smoking volunteers after i.v. bolus administration of 2-[18F]FA (1.6 MBq/kg or 0.043 +/- 0.002 mCi/kg). This dose was sufficient for visualizing nAChRs in the thalamus up to 5 h after injection. There were no adverse effects associated with administration of no-carrier-added 2-[18F]FA (1.3-10 pmol/kg). Consistent with the distribution of nAChRs in human brain, accumulated radioactivity was greatest in thalamus, intermediate in the midbrain, pons, cerebellum, and cortex; and least in white matter. As approximately 90{\%} of the injected radioactivity was eliminated via the urine (biological half-life ca. 4 h), the urinary bladder wall received the highest radiation dose. The estimate of radiation dose equivalent to the urinary bladder wall (ca. 180 +/- 30 mSv/MBq or 0.7 rem/mCi with a 2.4 h void interval) suggests that multiple studies could be performed in a single subject. The results predict that quantitative PET imaging of nAChRs in human brain with 2-[18F]FA is feasible.",
author = "Kimes, {Alane S.} and Andrew Horti and London, {Edythe D.} and Chefer, {Svetlana I.} and Carlo Contoreggi and Monique Ernst and Phyllis Friello and Koren, {Andrei O.} and Varughese Kurian and Matochik, {John A.} and Olga Pavlova and Vaupel, {D. Bruce} and Mukhin, {Alexey G.}",
year = "2003",
language = "English (US)",
volume = "17",
pages = "1331--1333",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "10",

}

TY - JOUR

T1 - 2-[18F]F-A-85380

T2 - PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans.

AU - Kimes, Alane S.

AU - Horti, Andrew

AU - London, Edythe D.

AU - Chefer, Svetlana I.

AU - Contoreggi, Carlo

AU - Ernst, Monique

AU - Friello, Phyllis

AU - Koren, Andrei O.

AU - Kurian, Varughese

AU - Matochik, John A.

AU - Pavlova, Olga

AU - Vaupel, D. Bruce

AU - Mukhin, Alexey G.

PY - 2003

Y1 - 2003

N2 - Noninvasive imaging of nicotinic acetylcholine receptors (nAChRs) in the human brain in vivo is critical for elucidating the role of these receptors in normal brain function and in the pathogenesis of brain disorders. Here we report the first in vivo visualization of human brain areas containing nAChRs by using PET and 2-[18F]fluoro-3-(2(S)azetidinylmethoxy)pyridine (2-[18F]FA). We acquired scans from six healthy non-smoking volunteers after i.v. bolus administration of 2-[18F]FA (1.6 MBq/kg or 0.043 +/- 0.002 mCi/kg). This dose was sufficient for visualizing nAChRs in the thalamus up to 5 h after injection. There were no adverse effects associated with administration of no-carrier-added 2-[18F]FA (1.3-10 pmol/kg). Consistent with the distribution of nAChRs in human brain, accumulated radioactivity was greatest in thalamus, intermediate in the midbrain, pons, cerebellum, and cortex; and least in white matter. As approximately 90% of the injected radioactivity was eliminated via the urine (biological half-life ca. 4 h), the urinary bladder wall received the highest radiation dose. The estimate of radiation dose equivalent to the urinary bladder wall (ca. 180 +/- 30 mSv/MBq or 0.7 rem/mCi with a 2.4 h void interval) suggests that multiple studies could be performed in a single subject. The results predict that quantitative PET imaging of nAChRs in human brain with 2-[18F]FA is feasible.

AB - Noninvasive imaging of nicotinic acetylcholine receptors (nAChRs) in the human brain in vivo is critical for elucidating the role of these receptors in normal brain function and in the pathogenesis of brain disorders. Here we report the first in vivo visualization of human brain areas containing nAChRs by using PET and 2-[18F]fluoro-3-(2(S)azetidinylmethoxy)pyridine (2-[18F]FA). We acquired scans from six healthy non-smoking volunteers after i.v. bolus administration of 2-[18F]FA (1.6 MBq/kg or 0.043 +/- 0.002 mCi/kg). This dose was sufficient for visualizing nAChRs in the thalamus up to 5 h after injection. There were no adverse effects associated with administration of no-carrier-added 2-[18F]FA (1.3-10 pmol/kg). Consistent with the distribution of nAChRs in human brain, accumulated radioactivity was greatest in thalamus, intermediate in the midbrain, pons, cerebellum, and cortex; and least in white matter. As approximately 90% of the injected radioactivity was eliminated via the urine (biological half-life ca. 4 h), the urinary bladder wall received the highest radiation dose. The estimate of radiation dose equivalent to the urinary bladder wall (ca. 180 +/- 30 mSv/MBq or 0.7 rem/mCi with a 2.4 h void interval) suggests that multiple studies could be performed in a single subject. The results predict that quantitative PET imaging of nAChRs in human brain with 2-[18F]FA is feasible.

UR - http://www.scopus.com/inward/record.url?scp=0037927968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037927968&partnerID=8YFLogxK

M3 - Article

C2 - 12759330

AN - SCOPUS:0037927968

VL - 17

SP - 1331

EP - 1333

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 10

ER -